Drug Trial Radar · NCT03179436
Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
Last checked: Nov 19, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
415
Actual
Start
Jul 2, 2017
Primary completion
Apr 8, 2024
Study completion Apr 8, 2024
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 7, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of quavonlimab when used in combination with pembrolizumab in participants with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
QuavonlimabBiological
Quavonlimab is administered intravenously (IV) during the Dose Escalation Phase and Dose Confirmation Phase at either DL1 or DL2, and is administered IV during the Efficacy Expansion Phase at DL2.
PembrolizumabBiological
Pembrolizumab is administered IV at PDL1 on Day 1 of each cycle starting Cycle 2 for the Dose Escalation Phase or starting Cycle 1 of the Dose Confirmation Phase. Pembrolizumab is administered IV at PDL2 on Day 1 of each cycle for the Efficacy Expansion Phase (Arm G).
Pembrolizumab/QuavonlimabDrug
Pembrolizumab/Quavonlimab is a coformulated product composed of quavonlimab at DL1 in combination with pembrolizumab at dose level 2 (PDL2).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With ≥1 Dose Limiting Toxicity (DLT)Time frame: Up to 6 weeks
- Number of Participants With ≥1 Adverse Event (AE)Time frame: Up to approximately 77 months
- Number of Participants Discontinuing Study Treatment Due to an AETime frame: Up to approximately 26 months
- Efficacy Expansion: Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) Based on Adjusted Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)Time frame: Up to approximately 72 months
Locations
53 sites in 16 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center ( Site 0013)
Gilbert, Arizona
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0005)
Hackensack, New Jersey
Tennessee Oncology Nashville ( Site 0004)
Nashville, Tennessee
South Texas Accelerated Research Therapeutics, LLC (START) ( Site 0001)
San Antonio, Texas
Inova Schar Cancer Institute ( Site 1001)
Fairfax, Virginia
Blacktown Hospital. Western Sydney local health district ( Site 0009)
Blacktown, New South Wales, Australia
Calvary Mater Newcastle ( Site 0025)
Waratah, New South Wales, Australia
Melanoma Institute Australia ( Site 0017)
Wollstonecraft, New South Wales, Australia
Gallipoli Medical Research Foundation-GMRF CTU ( Site 0019)
Brisbane, Queensland, Australia
Cairns and Hinterland Hospital and Health Service ( Site 0020)
Cairns, Queensland, Australia
Ashford Cancer Centre Research ( Site 0012)
Kurralta Park, South Australia, Australia
Ballarat Health Services ( Site 0022)
Ballarat, Victoria, Australia
Alfred Health ( Site 0018)
Melbourne, Victoria, Australia
Sunnybrook Research Institute ( Site 1103)
Toronto, Ontario, Canada
Princess Margaret Cancer Centre ( Site 1104)
Toronto, Ontario, Canada
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 1102)
Montreal, Quebec, Canada
Jewish General Hospital ( Site 1105)
Montreal, Quebec, Canada
McGill University Health Centre ( Site 1101)
Montreal, Quebec, Canada
Fundacion Arturo Lopez Perez ( Site 5601)
Santiago, Region M. de Santiago, Chile
Beijing Cancer hospital-Digestive Oncology ( Site 5001)
Beijing, Beijing Municipality, China
Chongqing Cancer Hospital-Phase 1 Unite ( Site 5004)
Chongqing, Chongqing Municipality, China
Sir Run Run Shaw Hospital-Medical Oncology ( Site 5003)
Hangzhou, Zhejiang, China
Hopital La Timone ( Site 3303)
Marseille, Bouches-du-Rhone, France
Institut Bergonie ( Site 3306)
Bordeaux, Gironde, France
CHRU Lille - Hopital Claude Huriez ( Site 3302)
Lille, Nord, France
CH Lyon Sud Hospices Civils de Lyon ( Site 3307)
Pierre-Bénite, Rhone, France
Gustave Roussy ( Site 3305)
Villejuif, Val-de-Marne, France
Regional General Hospital of Athens "Laiko" ( Site 3001)
Athens, Attica, Greece
Rambam Medical Center ( Site 0003)
Haifa, Israel
Hadassah Ein Karem Hebrew University Medical Center ( Site 0021)
Jerusalem, Israel
Sheba Medical Center - Cancer Center ( Site 0002)
Ramat Gan, Israel
Istituto Nazionale Tumori Fondazione Pascale ( Site 3903)
Naples, Italy
IRCCS Istituto Oncologico Veneto ( Site 3905)
Padova, Italy
Policlinico Le Scotte - A.O. Senese ( Site 3907)
Siena, Italy
National Cancer Center Hospital East ( Site 0014)
Kashiwa, Chiba, Japan
Hyogo Cancer Center ( Site 0015)
Akashi, Hyōgo, Japan
Auckland City Hospital ( Site 0016)
Auckland, New Zealand
Canterbury District Health Board ( Site 0023)
Christchurch, Canterbury, New Zealand
Szpital Kliniczny im. Heliodora Swiecickiego Uniwers Medyczn ( Site 4803)
Poznan, Greater Poland Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 4801
Warsaw, Masovian Voivodeship, Poland
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.